Buspirone/testosterone - Freya Pharma Solutions
Alternative Names: Buspirone/testosterone; LybridosLatest Information Update: 29 Aug 2022
At a glance
- Originator Emotional Brain
- Developer Companion Diagnostics BV; Emotional Brain
- Class Androstenols; Hormonal replacements; Pyrimidines; Small molecules; Spiro compounds; Testosterone congeners
- Mechanism of Action 5-HT1A serotonin receptor agonists; Androgen receptor agonists; Testosterone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Female sexual dysfunction
Most Recent Events
- 24 Aug 2022 Freya Pharma Solutions files for patent protection for improved treatment of Female Sexual Interest/Arousal Disorder (FSIAD)
- 12 Apr 2022 Freya Pharma Solutions plans a scientific advice meeting with the EMA for phase III trial in for Female sexual dysfunction
- 17 Dec 2021 Buspirone/testosterone - Freya Pharma Solutions is available for licensing as of 17 Dec 2021.